ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 41

Trends in Non-Cardiovascular Mortality in Patients with Incident Rheumatoid Arthritis: Is There Room for Improvement?

Elena Myasoedova1, Cynthia S. Crowson2, Eric L. Matteson3, John M. Davis III4 and Sherine E. Gabriel5, 1Internal Medicine and Rheumatology, Mayo Clinic, Rochester, MN, 2Health Sciences Research, Mayo Clinic, Rochester, MN, 3Rheumatology, Mayo Clinic, Rochester, MN, 4Division of Rheumatology, Mayo Clinic, Rochester, MN, 5Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: morbidity and mortality, respiratory disease and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 8, 2015

Title: Epidemiology and Public Health Poster I: Comorbidities and Outcomes of Systemic Inflammatory Diseases

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Rheumatoid arthritis (RA) is associated with increased all-cause and cause-specific mortality, including mortality from cardiovascular (CV) disease, respiratory causes, infections and malignancy. Evidence of improved overall mortality in RA is growing and decrease in CV mortality has been suggested in some studies including our own. Recent trends in non-CV mortality are not well understood. We aimed to assess trends in non-CV mortality including mortality from respiratory disease, neoplasms and other causes in patients with incident RA in 2000-2007 compared to the previous decades.

Methods: The study population comprised a retrospectively identified population-based incidence cohort of patients with RA (age>18 years, 1987 ACR criteria met in 1980-2007). All subjects were followed until death, migration, or 1/1/2014. Underlying causes of death were obtained from state and local death certificates as well as the National Death Index Plus and grouped according to ICD-9 and ICD-10 chapters. Kaplan-Meier methods were used to estimate mortality rates. Cox proportional hazards models, adjusting for age and sex, were used to compare cause-specific mortality by decade.

Results: The study included a total of 813 RA patients (mean age 55.9 years; 68% female; 66% rheumatoid factor [RF] positive). Figure shows non-CV mortality by decade of RA incidence and the table summarizes these data. In patients with incident RA during the 2000–2007 period, there was no statistically significant difference in 10-year mortality from non-CV causes overall (hazard ratio [HR] 0.92; 95% Confidence Interval [CI] 0.60 – 1.42; p=0.71), including mortality from respiratory disease (HR 1.51; 95% CI 0.56 – 4.09; p=0.42), neoplasms (HR 0.69; 95% CI 0.36 – 1.31; p=0.25) and other causes (HR 0.84; 95% CI 0.38 – 1.86; p=0.66) compared to those with RA incidence in 1990–1999.

Conclusion: Our findings suggest that there has been no significant improvement in mortality from non-CV causes overall among patients with incident RA in 2000-2007 compared to patients with incident RA in the previous decades. However, the trends in individual non-CV causes including respiratory disease, neoplasms and other causes may be heterogeneous and require caution in interpretation due to limited statistical power in our study. Lack of improvement in non-CV mortality in RA may be contributing to the persistent excess in relative mortality in RA vs non-RA subjects, suggesting a need for improved control of non-CV comorbidities in RA. More studies are needed to understand the underlying reasons for this lack of improvement in mortality from non-CV causes in RA patients.


Disclosure: E. Myasoedova, None; C. S. Crowson, None; E. L. Matteson, None; J. M. Davis III, None; S. E. Gabriel, None.

To cite this abstract in AMA style:

Myasoedova E, Crowson CS, Matteson EL, Davis JM III, Gabriel SE. Trends in Non-Cardiovascular Mortality in Patients with Incident Rheumatoid Arthritis: Is There Room for Improvement? [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/trends-in-non-cardiovascular-mortality-in-patients-with-incident-rheumatoid-arthritis-is-there-room-for-improvement/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/trends-in-non-cardiovascular-mortality-in-patients-with-incident-rheumatoid-arthritis-is-there-room-for-improvement/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology